OA02. 04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma-NCT03126630
Methods We designed a phase 1 safety run-in of the combination of anetumab ravtansine
(6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) followed by a phase 2 …
(6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) followed by a phase 2 …
OA02. 04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma-NCT03126630
AS Mansfield, JV Yin, P Bradbury… - Journal of Thoracic …, 2023 - Elsevier
Methods We designed a phase 1 safety run-in of the combination of anetumab ravtansine
(6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) followed by a phase 2 …
(6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) followed by a phase 2 …